1
|
Yang J, Zeng T, Yan K, Qin Z, Wen J. Direct Synthesis of Alkylthioimidazoles: One‐Pot Three‐Component Cross‐Coupling Mediated by Paired Electrolysis. Adv Synth Catal 2022. [DOI: 10.1002/adsc.202200259] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- Jianjing Yang
- Institute of Medicine and Materials Applied Technologies College of Chemistry and Chemical Engineering Qufu Normal University 273165 Qufu Shandong People's Republic of China
| | - Ting Zeng
- Institute of Medicine and Materials Applied Technologies College of Chemistry and Chemical Engineering Qufu Normal University 273165 Qufu Shandong People's Republic of China
| | - Kelu Yan
- Institute of Medicine and Materials Applied Technologies College of Chemistry and Chemical Engineering Qufu Normal University 273165 Qufu Shandong People's Republic of China
| | - Zonghui Qin
- College of Chemistry and Chemical Engineering Yangtze Normal University Fuling 408000 Chongqing People's Republic of China
| | - Jiangwei Wen
- Institute of Medicine and Materials Applied Technologies College of Chemistry and Chemical Engineering Qufu Normal University 273165 Qufu Shandong People's Republic of China
| |
Collapse
|
2
|
Sharma MK, Murumkar PR, Kuang G, Tang Y, Yadav MR. Identifying the structural features and diversifying the chemical domain of peripherally acting CB1 receptor antagonists using molecular modeling techniques. RSC Adv 2016. [DOI: 10.1039/c5ra20612j] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
A four featured pharmacophore and predictive 3D-QSAR models were developed which were used for virtual screening of the Asinex database to get chemically diverse hits of peripherally active CB1 receptor antagonists.
Collapse
Affiliation(s)
| | | | - Guanglin Kuang
- Shanghai Key Laboratory of New Drug Design
- School of Pharmacy
- East China University of Science and Technology
- Shanghai–200237
- China
| | - Yun Tang
- Shanghai Key Laboratory of New Drug Design
- School of Pharmacy
- East China University of Science and Technology
- Shanghai–200237
- China
| | - Mange Ram Yadav
- Faculty of Pharmacy
- The M. S. University of Baroda
- Vadodara–390 001
- India
| |
Collapse
|
3
|
Nettekoven M, Adam JM, Bendels S, Bissantz C, Fingerle J, Grether U, Grüner S, Guba W, Kimbara A, Ottaviani G, Püllmann B, Rogers-Evans M, Röver S, Rothenhäusler B, Schmitt S, Schuler F, Schulz-Gasch T, Ullmer C. Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases. ChemMedChem 2015; 11:179-89. [DOI: 10.1002/cmdc.201500218] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 06/23/2015] [Indexed: 11/05/2022]
Affiliation(s)
- Matthias Nettekoven
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Jean-Michel Adam
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Stefanie Bendels
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Catarina Bissantz
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Jürgen Fingerle
- Roche Pharmaceutical Research and Early Development; Discovery Biology; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Uwe Grether
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Sabine Grüner
- Roche Pharmaceutical Research and Early Development; Discovery Biology; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Wolfgang Guba
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Atsushi Kimbara
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Giorgio Ottaviani
- Roche Pharmaceutical Research and Early Development, DMPK; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Bernd Püllmann
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Mark Rogers-Evans
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Stephan Röver
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Benno Rothenhäusler
- Roche Pharmaceutical Research and Early Development, DMPK; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Sebastien Schmitt
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Franz Schuler
- Roche Pharmaceutical Research and Early Development, DMPK; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Tanja Schulz-Gasch
- Roche Pharmaceutical Research and Early Development; Small-Molecule Research; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| | - Christoph Ullmer
- Roche Pharmaceutical Research and Early Development; Discovery Biology; Roche Innovation Center Basel; Grenzacher Str. 124 4070 Basel Switzerland
| |
Collapse
|
4
|
Hu YP, Tang RY. TBHP-Mediated Oxidative Cross-Coupling of Disulfides with Ethers through a C(sp3)-H Thiolation Process. SYNTHETIC COMMUN 2014. [DOI: 10.1080/00397911.2014.888081] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Ya-Ping Hu
- a Food Science and Technology College , Hunan Agricultural University , Changsha , China
| | - Ri-Yuan Tang
- b College of Chemistry and Materials Engineering , Wenzhou University , Wenzhou , China
| |
Collapse
|
5
|
Tao LM, Liu WQ, Li CH, Liu H. TBHP-Mediated C–H Thiolation of Tetrahydrofuran with Disulfides Promoted by Catalytic Amounts of Na 2CO 3. JOURNAL OF CHEMICAL RESEARCH 2014. [DOI: 10.3184/174751914x13961795538392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
An efficient route to constructing C–S bonds has been developed by TBHP ( tert-butyl hydroperoxide) mediated C–H thiolation of tetrahydrofuran with disulfides. This route is promoted by catalytic amounts of Na2CO3 and gives various tetrahydrofuran-containing sulfides in moderate to high yields.
Collapse
Affiliation(s)
- Li-Ming Tao
- Hunan Provincial Key Laboratory of Xiangnan Rare-Precious Metals Compounds Research and Application, Department of Chemistry and Life Science, Xiangnan University, Chenzhou 423000, P.R. China
| | - Wen-Qi Liu
- Hunan Provincial Key Laboratory of Xiangnan Rare-Precious Metals Compounds Research and Application, Department of Chemistry and Life Science, Xiangnan University, Chenzhou 423000, P.R. China
| | - Chuan-Hua Li
- Hunan Provincial Key Laboratory of Xiangnan Rare-Precious Metals Compounds Research and Application, Department of Chemistry and Life Science, Xiangnan University, Chenzhou 423000, P.R. China
| | - Hui Liu
- Hunan Provincial Key Laboratory of Xiangnan Rare-Precious Metals Compounds Research and Application, Department of Chemistry and Life Science, Xiangnan University, Chenzhou 423000, P.R. China
| |
Collapse
|
6
|
Prospective therapeutic agents for obesity: Molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. Eur J Med Chem 2014; 79:298-339. [DOI: 10.1016/j.ejmech.2014.04.011] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Revised: 04/03/2014] [Accepted: 04/04/2014] [Indexed: 01/29/2023]
|
7
|
Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists. Eur J Med Chem 2014; 74:73-84. [DOI: 10.1016/j.ejmech.2013.12.018] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2013] [Revised: 11/21/2013] [Accepted: 12/19/2013] [Indexed: 12/25/2022]
|
8
|
Jiang XY, Liu ZC, Fang L, Yan SJ, Lin J. Construction of C(sp2)–S and C(sp2)–Se bonds via a silver(i)-mediated coupling reaction of heterocyclic ketene aminals with diaryl dichalcogenides. RSC Adv 2014. [DOI: 10.1039/c4ra02519a] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
A novel Ag(i)-mediated direct coupling reaction using HKAs and diaryl dichalcogenides for the construction of C(sp2)–chalcogenide bonds is reported. The transformation leads to a variety of α-arylthio and α-phenylselanyl HKAs with high regioselectivity and excellent yields.
Collapse
Affiliation(s)
- Xiu-Yang Jiang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University)
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P. R. China
| | - Zhi-Cheng Liu
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University)
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P. R. China
| | - Li Fang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University)
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P. R. China
| | - Sheng-Jiao Yan
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University)
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P. R. China
| | - Jun Lin
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University)
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P. R. China
| |
Collapse
|
9
|
Chang CP, Wu CH, Song JS, Chou MC, Wong YC, Lin Y, Yeh TK, Sadani AA, Ou MH, Chen KH, Chen PH, Kuo PC, Tseng CT, Chang KH, Tseng SL, Chao YS, Hung MS, Shia KS. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. J Med Chem 2013; 56:9920-33. [PMID: 24224693 DOI: 10.1021/jm401158e] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
After extensive synthetic efforts, we found that many structurally diverse bioisosteres could be generated via derivatizing the C-4 alkyl chain on the pyrazole ring of compound 3 (B/P = 1/33) with different electronegative groups. Especially when a sulfonamide or sulfamide moiety was added, resulting compounds exhibited not only potent CB1R activity but also a desired tPSA value over 90 Å(2), a threshold considered to possess a low probability to cross BBB, leading to the identification of compound 4 (B/P = 1/64) as a peripherally restricted CB1R antagonist. Apart from its significant weight-loss efficacy in DIO mice, compound 4 also displays 163 clean off-target profiles and is currently under development for treating obesity and the related metabolic syndrome.
Collapse
Affiliation(s)
- Chun-Ping Chang
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes , Miaoli County 35053, Taiwan, R.O.C
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Nettekoven M, Fingerle J, Grether U, Grüner S, Kimbara A, Püllmann B, Rogers-Evans M, Röver S, Schuler F, Schulz-Gasch T, Ullmer C. Highly potent and selective cannabinoid receptor 2 agonists: Initial hit optimization of an adamantyl hit series identified from high-through-put screening. Bioorg Med Chem Lett 2013; 23:1177-81. [DOI: 10.1016/j.bmcl.2013.01.044] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 01/09/2013] [Accepted: 01/12/2013] [Indexed: 10/27/2022]
|
11
|
Wittgen HGM, Greupink R, van den Heuvel JJMW, van den Broek PHH, Dinter-Heidorn H, Koenderink JB, Russel FGM. Exploiting Transport Activity of P-Glycoprotein at the Blood–Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists. Mol Pharm 2012; 9:1351-60. [DOI: 10.1021/mp200617z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Hanneke G. M. Wittgen
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| | - Rick Greupink
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| | - Jeroen J. M. W. van den Heuvel
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| | - Petra H. H. van den Broek
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| | | | - Jan B. Koenderink
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| | - Frans G. M. Russel
- Department of Pharmacology and Toxicology,
Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, The Netherlands
| |
Collapse
|
12
|
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50:193-211. [PMID: 21295074 DOI: 10.1016/j.plipres.2011.01.001] [Citation(s) in RCA: 311] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2010] [Revised: 01/26/2011] [Accepted: 01/26/2011] [Indexed: 12/19/2022]
Abstract
The mammalian body has a highly developed immune system which guards against continuous invading protein attacks and aims at preventing, attenuating or repairing the inflicted damage. It is conceivable that through evolution analogous biological protective systems have been evolved against non-protein attacks. There is emerging evidence that lipid endocannabinoid signaling through cannabinoid 2 (CB₂) receptors may represent an example/part of such a protective system/armamentarium. Inflammation/tissue injury triggers rapid elevations in local endocannabinoid levels, which in turn regulate signaling responses in immune and other cells modulating their critical functions. Changes in endocannabinoid levels and/or CB₂ receptor expressions have been reported in almost all diseases affecting humans, ranging from cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, autoimmune, lung disorders to pain and cancer, and modulating CB₂ receptor activity holds tremendous therapeutic potential in these pathologies. While CB₂ receptor activation in general mediates immunosuppressive effects, which limit inflammation and associated tissue injury in large number of pathological conditions, in some disease states activation of the CB₂ receptor may enhance or even trigger tissue damage, which will also be discussed alongside the protective actions of the CB₂ receptor stimulation with endocannabinoids or synthetic agonists, and the possible biological mechanisms involved in these effects.
Collapse
|